Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07292272

Halt Aging in Survivors of Blood Cancers

Older survivors of blood cancer are at a high risk of accelerated biological aging, which increases their risk of developing multiple aging-related conditions. Whereas physical exercise can improve overall health, older cancer survivors do not meet the recommended physical activity, highlighting the need to develop behavioral interventions to increase adherence. Several other knowledge gaps exist to implement exercise interventions in older survivors of blood cancer; the dose and duration of exercise necessary to slow biological aging in older blood cancer survivors remain unknown. To bridge these gaps in knowledge, we have designed a Phase 2 randomized control trial to test the effects of behavioral and exercise interventions on various outcomes.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hematological Malignancy Blood Protein Disorders Cardiovascular Diseases Hematologic Diseases Hematologic Neoplasms Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Hodgkin Disease Immune System Diseases Immunoproliferative Disorders Leukemia Leukemia, Lymphoid Leukemia, Monocytic, Acute Leukemia, Myeloid Leukemia, Myeloid, Acute Lymphatic Diseases Lymphoid Leukemia Lymphoma Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Monocytic Leukemia Multiple Myeloma Myeloid Leukemia Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Plasma Cell Non-Hodgkin Lymphoma Other Hematologic Condition Paraproteinemias Vascular Diseases

Age range

50 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Nebraska Medical Center

Omaha, Nebraska, 68008, United States

Location status: Recruiting

Location contact

IIT Office IIT Office

CONTACT

[email protected]

402-559-4596

Vijaya Bhatt, MBBS

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥50 years
  • A history of hematological malignancy
  • Participants must be able to and willingly give informed consent

Exclusion criteria

  • Patients receiving intensive induction or consolidation chemotherapy. Maintenance chemotherapy, or lower-intensity chemotherapy for an indolent hematological malignancy is allowed.
  • Neurodegenerative disease (e.g. Alzheimer's dementia), stroke, or uncontrolled psychotic disorders (e.g. schizophrenia or bipolar disorder) in the past 3 months if those disorders are considered significant enough to impair participation in the study.
  • Illnesses such as clinical evidence of decompensated heart failure, unstable angina, or orthopedic or neuromuscular disorders that could limit safe participation in aerobic exercise.
  • Cardiopulmonary exercise test results that preclude safe exercise (e.g., life-threatening arrhythmia, balance difficulties, peak VO2 <10 ml/kg/min).
  • Estimated life expectancy of less than 6 months (that precludes assessment of study primary endpoint).
  • Self-reported pregnancy or the possibility of pregnancy.
  • Participants who do not plan to follow up at the participating center.

Treatment and study plan

Behavioral Coaching Intervention

Behavioral

Intervention arm incorporating virtually supervised moderate-intensity aerobic exercise and behavioral intervention/coaching to improve adherence

Virtual Exercise Platform

Behavioral

Access to a virtual exercise platform that provides exercise classes and educational sessions for older survivors of blood cancer

Primary outcomes

  1. Percentage of participants who adhered to the exercise regimen at 6-months post enrollment.

    Time frame: 6 Months from start of program

    Participants achieving at least 120 minutes per week of moderate-intensity aerobic exercise, measured using Polar heart rate monitor data and exercise diaries.

  2. Percentage of participants who adhered to the exercise regimen at 12-months post enrollment.

    Time frame: 12 Months from start of program.

    Participants achieving at least 120 minutes per week of moderate-intensity aerobic exercise, measured using Polar heart rate monitor data and exercise diaries to assess sustainability of adherence.

Secondary outcomes

  1. Physical Function (6- Minute Walk Test Distance)

    Time frame: 6 months from randomization

    Distance covered during the 6-minute walk test (6MWT) to assess physical function.

Other outcomes

  1. Physical Function Maximal Oxygen Consumption (VO₂ max)

    Time frame: 6 months from randomization

    Maximal oxygen consumption measured during cardiopulmonary exercise testing (CPET)

  2. Neuro-QOL Cognition Function Short Form Score

    Time frame: 6 months from randomization

    Subjective cognitive function assessed using the Neuro-QOL v2.0 Cognition Function Short Form

  3. Trail Making Test Performance

    Time frame: 6 months from randomization

    Cognitive function assessed using Trail Making Test Parts A and B (TMT-A and TMT-B).

  4. Controlled Oral Word Association Test Performance

    Time frame: 6 months from randomization

    Cognitive function assessed using the Controlled Oral Word Association Test (COWAT).

  5. EORTC QLQ-C30 Score

    Time frame: 6 months from randomization

    Health-related quality of life assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), version 3.0.

  6. EQ-5D-5L Score

    Time frame: 6 months from randomization

    Health-related quality of life assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) instrument.

  7. Biological Age by Epigenetic Clock

    Time frame: 6 months from randomization

    Change in biological age assessed using epigenetic clock biomarkers based on DNA methylation analysis.

Study contacts

Contact information is provided by the study sponsor or research team.

IIT OFFICE

CONTACT

[email protected]

402-559-4596

Taylor Johnson

CONTACT

[email protected]

402-559-4596

Sponsors and collaborators

Lead sponsor

University of Nebraska

Other

Registry information

Official study title

Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study

Acronym: HALTAging-1

Important dates

Study start
2026
Primary completion
2032
Study completion
2033
First posted
Dec 18, 2025
Registry last updated
Jul 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.